Evolution of the treatment procedures so that their is no more benefits for patients

The study of volatile organic compounds (VOC) detected in exhaled air or in sweat, is an innovative research area for respiratory diseases. The volatolomic analysis can be done either by the technique of the mass spectrometry which allows the identification of each VOC in the exhaled air or by the technique of electronic nose, simpler and faster, which provides an idea of the general profile of the VOC without identifying them. The VOC have shown their interest in some situations, such as diagnostic or prognostic tool in patients followed for thoracic tumorous pathology or bronchial or pulmonary vascular diseases.

Immunotherapy is a new therapeutic approach used in non small cell lung cancer in a late stage.

VOC analysis could allow to identify biomarkers of early response to immunotherapy. The study of VOC could help in the optimisation of immunotherapy prescription in lung cancer.

Inclusion Criteria:

• patient aged > 18 years old
• patient with metastatic non-small cell lung cancer with marketing authorisation criteria for immunotherapy
• preserved overall condition (Performans Status 1)
• signed informed consent
• patient with healthcare insurance

Non Inclusion Criteria:

• patient with oxygen therapy or invasive ventilation
• patient unable to perform a slow vital capacity
• systemic corticosteroid therapy more than 10 mg per day of prednisone equivalent
• previous treatment with immunotherapy
• dermatological therapy interfering with sweat collection (psoriasis, irritant dermatitis, for instance)
• Patient deprived of liberty by judicial or administrative decision